Find information on thousands of medical conditions and prescription drugs.
Capecitabine (brand name: Xeloda®) is an orally-administered chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. It is enzymatically converted to fluorouracil in the body, where it inhibits DNA synthesis and slows growth of tumor tissue. more...
Capecitabine is FDA-approved for:
Metastatic Colorectal Cancer
- Used as first-line monotherapy, if appropriate.
Metastatic Breast Cancer
- Used in combination with docetaxel, after failure of anthracycline-based treatment.
- Used as monotherapy, if the patient has failed paclitaxel-based treatment, and if anthracycline-based treatment has either failed or cannot be continued for other reasons (i.e., the patient has already received the maximum lifetime dose of an anthracycline).
The usual starting dose is 2,500 mg/m2/day in two divided doses, 12 hours apart. One cycle includes two weeks of treatment followed by one week without treatment. Cycles can be repeated every three weeks.
- For mild renal dysfunction (creatinine clearance 30-50 mL/min), it is recommended to reduce dose by 25%.
- For severe renal dysfunction (creatinine clearance <30 mL/min), treatment is not recommended.
- There is no recommendation for hepatic dysfunction.
- For elderly patients, lower doses may be required due to higher incidences of serious adverse reactions.
Take orally with water, within 30 minutes after a meal.
Potential Adverse Reactions (Major)
- Cardiovascular: EKG changes, myocardial infarction, angina (these may be more common in patients with pre-existing coronary artery disease)
- Dermatological: Hand-foot syndrome (numbness, tingling, pain, redness, or blistering of the palms of the hands and soles of the feet)
- Gastrointestinal: Diarrhea (sometimes severe), nausea, stomatitis
- Hematological: Neutropenia, anemia, thrombocytopenia
- Hepatic: Hyperbilirubinemia
- Capecitabine may interact with warfarin and increase bleeding risk. It is recommended to watch coagulation levels (INR) closely and adjust warfarin doses appropriately.
- Capecitabine may inhibit cytochrome CYP2C9 enzyme, and therefore increase levels of substrates such as phenytoin. It is recommended to monitor phenytoin levels in patients taking both medications. Other substrates of CYP2C9 may also be affected. Evaluate according to clinical judgment.
- Much as fluorouracil, the concomitant use of leucovorin may increase both the efficacy and the toxicity of capecitabine.
Pregnancy / Lactation Information
- Capecitabine is pregnancy category D. Women of childbearing potential are advised to avoid becoming pregnant while using capecitabine.
- Significant amounts of capecitabine may be excreted into the breast milk. It is recommended to discontinue nursing while using capecitabine.
Read more at Wikipedia.org
• [List your site here Free!]
|First case report of Xeloda induced coronary artery disease.(Section on Oncology) : An article from: Southern Medical Journal $5.95||
Xeloda/Taxotere breast cancer therapy gets FDA endorsement - Roche, Aventis - Brief Article|
Xeloda/Taxotere breast cancer therapy gets FDA endorsement.(Roche, Aventis)
From Drug Store News,
Drug combination approved for advanced breast cancer - Updates - Xeloda and Taxotere - Brief Article|
Two drugs already on the market to treat breast cancer have been approved by the FDA to be used in combination for an even greater effect in treating ...
From FDA Consumer,
New drug OK'd for hard-to-treat breast cancer - FDA approves Xeloda, manufactured by Hoffmann-La Roche Inc - Brief Article|
Women with hard-to-treat breast cancer now have another option for managing their potentially life-threatening disease. The oral treatment Xeloda ...
From FDA Consumer,
[Xeloda.sup.TM] OK'd to treat tumors in women|
[Xeloda.sup.TM] (capecitabine), produced by Hoffmann-La Roche Inc., has been granted accelerated approval as a new oral treatment available for women with tumors resistant to treatment by other means
From Drug Store News,
Pharmaceutical: top 50 packages|
From Food & Drug Packaging,
Oral Chemotherapy Xeloda Shown to Extend Survival for Patients with Pancreatic Cancer|
- Data show significant survival benefit in fighting aggressive cancer - NUTLEY, N.J., Nov. 2 /PRNewswire/ -- The interim analysis of one of the largest phase III studies investigating the first
From PR Newswire,
Fda Approves Lorus/Nci Gti-2040 Phase Ii Clinical Trial|
Lorus Therapeutics Inc., Toronto, Canada, has announced that the U.S. Food and Drug Administration has approved the U.S. National Cancer Institute's ...
From Worldwide Biotech,
How Well Tested Are the New Cancer Drugs?|
With a certain amount of regularity a new cancer drug makes headlines, generating an enormous amount of hope, as well as pressure to make the product ...
by Maryann Napoli